ArticleFrontiers in microbiology2025
Bactericidal activity of ceragenin CSA-13, CSA-44 and CSA-131 against bacteria causing bloodstream infections.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The constantly growing resistance of bacteria causing bloodstream infections and the lack of alternative antibiotics generate the need to develop new therapeutic strategies. In this study, the antibacterial properties of synthetic cholic acid derivatives ceragenins CSA-13, CSA-44 and CSA-131, custom-synthesized peptides human cathelicidin LL-37 peptide, synthetic WLBU2 peptide, and antimicrobial VFR12 peptide of human thrombin origin were evaluated to determine their potentials as therapeutic agents for bloodstream infections. Methods: Minimum inhibitory concentrations/minimum bactericidal concentrations (MIC/MBC) against clinical bacterial strains were measured and compared with activity of clinically used antibiotics colistin and vancomycin. Therapeutic potentials of the tested agents were assessed in the presence of 50% blood plasma, and their hemolytic properties were determined using human red blood cells (RCB). Additionally, the antimicrobial activity of CSA-13 against selected clinical strains was assessed using a killing assay. Plasma cytokine levels were determined, and endothelial cell confluent monolayer permeability was assessed using the FITC-dextran and measurement of transepithelial electrical resistance (TEER). Results: Under experimental conditions mimicking blood environment, ceragenins display higher antimicrobial activity compared to the cationic peptides regardless of the bacterial species. The presence of blood plasma slightly decreases the effect of ceragenins but does not significantly affect their antibacterial properties or their hemolytic activity, especially in case of ceragenin CSA-13. Furthermore, ceragenins at bactericidal concentrations do not induce hemolysis of red blood cells. CSA-13 dose-dependently regulates the permeability of human umbilical vein endothelial cells (HUVECs) monolayers as well as affects the secretion of cytokines, which may indicate its ability to modulate immune responses. Conclusion: Results presented herein demonstrate the antibacterial activity of ceragenins against clinical strains of bacteria isolated from blood, their influence on the immune system and the integrity of the endothelial cell monolayer. Further studies are necessary to understand the cell signaling pathway governing these effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.